Clinical Trial Update: AE-941 in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 trial of AE-941 for relapsed or refractory Multiple Myeloma has been completed, reported by AEterna Zentaris.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Neoplasm

Drugs mentioned

• AE-941

Snippet

Sponsor: AEterna Zentaris | Conditions: Multiple Myeloma and Plasma Cell Neoplasm | Phase 2 | Status: COMPLETED